Newron Pharmaceuticals SpA (FRA:NP5) Shares Outstanding (Basic Average): 19.97 Mil (As of Dec. 2025)


FRA:NP5 Newron Pharmaceuticals SpA FRA:NP5
65 GF Score
Price €13.35
GF Value €13.83
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Newron Pharmaceuticals SpA Shares Outstanding (Basic Average)?

Newron Pharmaceuticals SpA FRA:NP5 +4.30% 65 Shares Outstanding (Basic Average) is 19.97 Mil as of Dec. 2025. GuruFocus rates FRA:NP5 with a GF Score™ of 65/100 and a GF Value™ of €13.83 (Fairly Valued). The stock has 5 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Newron Pharmaceuticals SpA's average basic shares outstanding for the quarter that ended in Dec. 2025 was 19.97 Mil.


Newron Pharmaceuticals SpA  (FRA:NP5) Shares Outstanding (Basic Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.


Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Newron Pharmaceuticals SpA Shares Outstanding (Basic Average) Related Terms


Newron Pharmaceuticals SpA Shares Outstanding (Basic Average) Historical Data

* Premium members only.

The historical data trend for Newron Pharmaceuticals SpA's Shares Outstanding (Basic Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Newron Pharmaceuticals SpA Shares Outstanding (Basic Average) Chart

Newron Pharmaceuticals SpA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shares Outstanding (Basic Average)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.85 17.85 17.85 18.56 19.96

Newron Pharmaceuticals SpA Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Shares Outstanding (Basic Average) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.85 18.56 18.56 19.96 19.97
FRA:NP5
65GF Score
Newron Pharmaceuticals SpA FRA:NP5
Shares Outstanding (Basic Average) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Newron Pharmaceuticals SpA Shares Outstanding (Basic Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (Basic Average) of 19.97 Mil mean?
Newron Pharmaceuticals SpA (FRA:NP5) has a Shares Outstanding (Basic Average) of 19.97 Mil as of Dec. 2025. The average shares outstanding over two periods not accounting for dilutive securities like convertible bonds. View historical data on Newron Pharmaceuticals SpA and its competitors.
Is Newron Pharmaceuticals SpA's Shares Outstanding (Basic Average) too high?
Newron Pharmaceuticals SpA's current Shares Outstanding (Basic Average) is 19.97 Mil. Overall, Newron Pharmaceuticals SpA has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Newron Pharmaceuticals SpA's Shares Outstanding (Basic Average) compare to VRTX and REGN?
Newron Pharmaceuticals SpA's Shares Outstanding (Basic Average) of 19.97 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (Basic Average) for a Biotechnology company?
A good Shares Outstanding (Basic Average) depends on the Biotechnology industry context. However, Shares Outstanding (Basic Average) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (Basic Average) mean?
A high Shares Outstanding (Basic Average) can signal that a stock is expensive relative to its fundamentals. The average shares outstanding over two periods not accounting for dilutive securities like convertible bonds. View historical data on Newron Pharmaceuticals SpA and its competitors. Newron Pharmaceuticals SpA's current Shares Outstanding (Basic Average) is 19.97 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Newron Pharmaceuticals SpA stock overvalued right now?
Based on GuruFocus' analysis, Newron Pharmaceuticals SpA (FRA:NP5) is currently considered Fairly Valued. The stock's GF Value™ is €13.83, compared to a current price of €13.35 — trading 3.5% below its estimated fair value. The current Shares Outstanding (Basic Average) is 19.97 Mil. Newron Pharmaceuticals SpA's overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (Basic Average) calculated?
Shares Outstanding (Basic Average) is calculated from a company's financial statements. For Newron Pharmaceuticals SpA (FRA:NP5), the current Shares Outstanding (Basic Average) is 19.97 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Newron Pharmaceuticals SpA (FRA:NP5) Overvalued in 2026?

Based on GuruFocus' analysis, Newron Pharmaceuticals SpA stock appears to be undervalued. The current stock price of €13.35 is trading 3.5% below its estimated GF Value™ of €13.83. GuruFocus considers Newron Pharmaceuticals SpA to be Fairly Valued.

Key valuation signals for FRA:NP5:

  • Shares Outstanding (Basic Average): 19.97 Mil
  • GF Value™: €13.83 vs. price of €13.35 (3.5% below fair value)
  • GF Score™: 65/100 with 5 warning signs

No single metric tells the full story. See the FRA:NP5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Newron Pharmaceuticals SpA Business Description

Address Via Antonio Meucci 3, Bresso, Milan, ITA, 20091
Newron Pharmaceuticals SpA is a Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson's disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Geographically the research and development activities are performed in Italy and the United States.
65GF Score

Get the complete analysis for FRA:NP5

Shares Outstanding (Basic Average) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€13.35
Price
€13.83
GF Value